Phio Pharmaceuticals News Releases http://investors.rxipharma.com/ Phio Pharmaceuticals News Releases en Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-present-sachs-associates-5th-annual-immuno Will Also Attend 2019 ASCO Annual Meeting MARLBOROUGH, Mass. , May 20, 2019 /PRNewswire/ --  Phio Pharmaceuticals Corp.  (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA ® ) therapeutic Mon, 20 May 2019 07:05:00 -0400 Phio Pharmaceuticals News Releases 10551 Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-reports-first-quarter-2019-financial - Expansion of Industry Partners With Glycostem Therapeutics BV Collaboration - Dr. John A. Barrett Appointed as Chief Development Officer - Reiterates Cash Expected to Provide Funding Into Second Half of 2020 MARLBOROUGH, Mass. , May 14, 2019 /PRNewswire/ --  Phio Pharmaceuticals Corp. Tue, 14 May 2019 17:22:00 -0400 Phio Pharmaceuticals News Releases 10531 Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-appoints-dr-john-barrett-chief-development MARLBOROUGH, Mass. , April 10, 2019 /PRNewswire/ --  Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA ® ) therapeutic platform, today announced the appointment of Wed, 10 Apr 2019 07:05:00 -0400 Phio Pharmaceuticals News Releases 10501 Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment http://investors.rxipharma.com/news-releases/news-release-details/phio-and-glycostem-collaborate-use-its-sd-rxrnar-platform-and MARLBOROUGH, Mass. , March 28, 2019 /PRNewswire/ --  Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in Thu, 28 Mar 2019 07:05:00 -0400 Phio Pharmaceuticals News Releases 10481 Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-reports-fourth-quarter-and-year-end-2018 - Gerrit Dispersyn Appointed as President and Chief Executive Officer - Cash Position Expected to Provide Funding Into the Second Half of 2020 - Expansion of Immuno-Oncology Pipeline With Industry and Academic Collaborations MARLBOROUGH, Mass. , March 27, 2019 /PRNewswire/ --  Phio Pharmaceuticals Wed, 27 Mar 2019 17:20:00 -0400 Phio Pharmaceuticals News Releases 10466 Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-present-poster-use-self-delivering-rnai MARLBOROUGH, Mass. , March 25, 2019 /PRNewswire/ --  Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA ® ) therapeutic platform, announced today that the Company Mon, 25 Mar 2019 07:05:00 -0400 Phio Pharmaceuticals News Releases 10451 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-appoints-gerrit-dispersyn-new-chief - CEO Geert Cauwenbergh to Retire and Remain on Board of Directors - MARLBOROUGH, Mass. , Feb. 15, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced that Gerrit Dispersyn, Dr. Med. Sc., currently President and COO, has been appointed by the Board of Directors as the Fri, 15 Feb 2019 07:15:00 -0500 Phio Pharmaceuticals News Releases 10391 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-present-biotech-showcasetm-2019-san MARLBOROUGH, Mass. , Dec. 18, 2018 /PRNewswire/ -- Phio Pharmaceuticals Corp.  (NASDAQ: PHIO) (formerly RXi Pharmaceuticals Corporation ), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic Tue, 18 Dec 2018 07:05:00 -0500 Phio Pharmaceuticals News Releases 10331 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 http://investors.rxipharma.com/news-releases/news-release-details/phio-pharmaceuticals-present-tumor-targeted-lymphocytes-summit MARLBOROUGH, Mass. , Dec. 4, 2018 /PRNewswire/ --  Phio Pharmaceuticals Corp.  (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced that Dr. Tue, 04 Dec 2018 07:05:00 -0500 Phio Pharmaceuticals News Releases 10306 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. http://investors.rxipharma.com/news-releases/news-release-details/rxi-pharmaceuticals-corporation-changes-name-phio -Reflects Company's Transition to Develop Groundbreaking Immuno-Oncology Therapeutics- -Trading Under Nasdaq Symbol "PHIO" Begins Today, November 19- MARLBOROUGH, Mass., Nov. 19, 2018 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:  PHIO ), a biotechnology company developing the next generation Mon, 19 Nov 2018 07:00:00 -0500 Phio Pharmaceuticals News Releases 10276